SEC Filing Summary: Hemispherx Biopharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Hemispherx Biopharma, Inc. on July 29, 2013, covering events occurring on July 23, 2013. The filing addresses corporate governance changes within the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters.
Material Changes
The primary material change reported is the restructuring of the Board of Directors following the resignation of Richard C. Piani due to health reasons. Key appointments include:
- Peter W. Rodino III, Esq.: Appointed as a Director, effective July 23, 2013. He serves until the next annual shareholder meeting. Additionally, he was appointed Chairman and Financial Expert of the Audit Committee, and as a member of both the Compensation Committee and the Governance and Nomination Committee. Mr. Rodino previously served as a consultant to the Company.
- Dr. Iraj Kiani: Appointed as the Board's Lead Director. Dr. Kiani is a long-time independent Director.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies were disclosed in this report, other than the context of the resignation due to health reasons.
Key Facts for Investor Verification
- Verify the effective date of Peter W. Rodino III's appointment as Director and Committee Chair (July 23, 2013).
- Confirm the reason for Richard C. Piani's departure (health reasons).
- Review the attached press release (Exhibit 99.1) dated July 29, 2013, for further details on the appointments.
- Note that this filing does not contain financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.